New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2013
20:01 EDTVNDAVanda says FDA grants priority review for tasimelteon NDA
Vanda Pharmaceuticals announced that the U.S. FDA has accepted the filing and granted a priority review classification to Vanda's New Drug Application for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder in the totally blind. The FDA determined the action target date under Prescription Drug User Fee Act, to be January 31, 2014. The FDA has also tentatively scheduled an advisory committee meeting to discuss the tasimelteon application on November 14.
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 14, 2014
11:46 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
August 13, 2014
10:33 EDTVNDAOptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
August 12, 2014
11:15 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
August 11, 2014
11:28 EDTVNDAOptions with decreasing implied volatility
Options with decreasing implied volatility: GRPN MNKD UBNT OLED ZU RPTP SALE UNXL FEYE VNDA
06:03 EDTVNDAVanda pullback a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the post-earnings pullback in shares of Vanda Pharmaceuticals as a buying opportunity. Piper says Hetlioz is launching well and that it sees no reason to back off its bullish stance or $25 price target. The firm reiterates an Overweight rating on the name.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use